Scancell Holdings PLC to use needle-free technology for next-generation vaccine candidates, featuring PharmaJet

Scancell Holdings PLC (AIM:SCLP, FRA:SCP) (AIM:SCLP) said it will use PharmaJet’s needle-free technology to administer Covid vaccine candidates SCOV1 and SCOV2 in its COVIDITY phase I clinical trial.

Researchers will use either the Tropis system for intradermal delivery or the Stratis product for intramuscular use.

“Our preclinical studies have shown that delivery of SCOV1 and SCOV2 with the PharmaJet needle-free systems generate excellent T-cell and antibody responses,” said Scancell’s chief executive, Professor Lindy Durrant.

“In addition, they are easy to use and ideal for people who are needle phobic, an important cause of vaccine hesitancy.”

The regulatory authorities in South Africa signed off the initial stage of the COVIDITY study last month.

The programme is a collaboration between Scancell and scientists in the newly established Centre for Research on Global Virus Infections and the new Biodiscovery Institute at the University of Nottingham and Nottingham Trent University. It has received funding from Innovate UK.